@Gussington did generalise: pre commercialisation, where revenue is less than expenses such as R&D and the like, is always going to be a slow increase in market cap relative to the share price.
Correction: ... is sometimes going to be a slow increase in market cap ...
And sometimes a complete duster, which becomes worthless.
I'm not a particularly insightful investor / stock-watcher, but I can only conclude that in Biotech especially, stocks with merit far outnumber stocks which reach success.
I'm holding a modest parcel, and I've buying in and selling out of this company for years. Not now or ever would I consider it a safe bet, of even avoiding a crash to 25% of current valuation.
Is it worth the risk ...?
Oh, yeah ... sort of. If you like risk.
I don't mind jumping in where fools fear to tread.
In other words, invest in it if you can afford to lose it.
TAVR MARKET Superiority, page-78
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
0.000(0.00%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.30 | $19.00 | $18.00 | $363.4K | 19.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 500 | $18.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.50 | 1000 | 1 |
View Market Depth
| Last trade - 15.59pm 01/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |